Getfitinib Articles
European oncologists indicate Tarceva will threaten market position of Iressa in mutated EGFR NSCLC
2 November 2011
Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche
28 July 2010
In a world first, Asda announces 'not for profit' UK price on all cancer treatment drugs
21 May 2010
NICE requests more data on AstraZeneca’s Iressa for NSC lung cancer, notably on cost effectiveness
29 January 2010
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
18 December 2009
64% of BIBW 2992 patients see PR
18 May 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
NSCLC data could signal comeback for AZ's Iressa
1 December 2008
AstraZeneca submits MAA for Iressa
12 May 2008
Free lung cancer drugs donated in China
28 January 2008
World Conference on Lung Cancer highlights important developments
17 September 2007
AstraZeneca's R&D pipeline update reveals 120 NCEs and 25 LCM strategies in progress
12 February 2007
Introgen gains rights to therapies combining EGFr inhibitors
13 November 2006
US FDA posts DSOB meeting summary
15 August 2005
Astra Zeneca 2nd-qtr pretax profit leaps 67%
8 August 2005
AstraZeneca sees 2nd-qtr pretax profit leap 67%
1 August 2005
Stock Commentary - Europe
30 May 2005
Stock Commentary - Europe
23 May 2005
Genasense shows strong combination performance
25 April 2005
NCI halts Iressa trial on lack of efficacy
25 April 2005
Astrazeneca strive for Iressa authorization
14 March 2005
ViroLogic to conduct biomarker trial of Iressa
14 March 2005
AstraZeneca shares poor trial result
7 February 2005
Stock Commentary - Europe
7 February 2005
AstraZeneca shares poor trial result
7 February 2005
AstraZeneca shares up on 16% hike in 2004 pretax profit
31 January 2005
Iressa's survival benefit to oriental patients?
31 January 2005
Slowdown in revenue growth forecast for AstraZeneca
31 January 2005
Stock Commentary - Europe
10 January 2005
AstraZeneca pulls EU MAA for Iressa
10 January 2005
AstraZeneca shares slump as promotion of Iressa is suspended
10 January 2005
AstraZeneca's Iressa shows no overall survival advantage
10 January 2005
AstraZeneca's EPS up 56%, sales rise 10%
1 November 2004
New cancer drug costs too high for some?
25 October 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
New NSCLC trial for AstraZeneca's Iressa
20 September 2004
30% 1-yr survival with gefitinib in NSCLC
13 September 2004
Stock Commentary - New York
6 September 2004
AstraZeneca's Iressa "Oncology Compound of Year"
6 September 2004
AstraZeneca's 2nd-qtr sales jump 19%
2 August 2004
AstraZeneca's 1st-qtr sales pass $5 billion
3 May 2004
AstraZeneca forecasts good growth in Spain
3 May 2004
Cancer drug developments and attitudes in Japan
26 April 2004
Over 400 deaths linked to Iressa in Japan
5 April 2004
Japanese pharma and devices agencies merge
5 April 2004
$1-$13 million a day at risk from product launch delays
22 March 2004
AstraZeneca's Iressa gets first European approval
15 March 2004
OSI/Genentech/Roche's Tarceva filed in USA
2 February 2004
NDAs rise 20% as R&D, marketing unite: study
22 December 2003
New wave of drugs offer hope in treatment of colon cancer
3 November 2003
As R&D and marketing unite, NME numbers rise: study
3 November 2003
AstraZeneca raises full-year earnings guidance
28 July 2003
Majors rush to roll out new drugs in Japan
14 July 2003
Stock Commentary - Europe
9 June 2003
Stock Commentary - Europe
19 May 2003
Stock Commentary - Europe
12 May 2003
Second approval for Iressa in Australia
12 May 2003
UK NICE to view statins, antipsychotics, etc
7 April 2003
Japanese legal threat to AstraZeneca over Iressa
24 March 2003
AstraZeneca denies Iressa wrongdoing in Japan
3 March 2003
Stock Commentary - Week to Feb 17 - Europe
24 February 2003
Update: AstraZeneca to do safety trial of Iressa
17 February 2003
AstraZeneca to do safety trial of Iressa
17 February 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Japanese drugmakers increase drug side effect monitoring
3 February 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
